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Considerable evidence suggests that transmission at hypocretin-1 (orexin-1) receptors
(Hcrt-R1) plays an important role in the reinstatement of extinguished cocaine-seeking
behaviors in rodents. However, far less is known about the role for hypocretin transmission
in regulating ongoing cocaine-taking behavior. Here, we investigated the effects of the
selective Hcrt-R1 antagonist SB-334867 on cocaine intake, as measured by intravenous
(IV) cocaine self-administration in rats. The stimulatory effects of cocaine on brain reward
systems contribute to the establishment and maintenance of cocaine-taking behaviors.
Therefore, we also assessed the effects of SB-334867 on the reward-enhancing properties
of cocaine, as measured by cocaine-induced lowering of intracranial self-stimulation
(ICSS) thresholds. Finally, to definitively establish a role for Hcrt-R1 in regulating cocaine
intake, we assessed IV cocaine self-administration in Hcrt-R1 knockout mice. We found
that SB-334867 (1–4mg/kg) dose-dependently decreased cocaine (0.5mg/kg/infusion)
self-administration in rats but did not alter responding for food rewards under the
same schedule of reinforcement. This suggests that SB-334867 decreased cocaine
reinforcement without negatively impacting operant performance. SB-334867 (1–4mg/kg)
also dose-dependently attenuated the stimulatory effects of cocaine (10mg/kg) on brain
reward systems, as measured by reversal of cocaine-induced lowering of ICSS thresholds
in rats. Finally, we found that Hcrt-R1 knockout mice self-administered far less cocaine
than wildtype mice across the entire dose-response function. These data demonstrate
that Hcrt-R1 play an important role in regulating the reinforcing and reward-enhancing
properties of cocaine and suggest that hypocretin transmission is likely essential for
establishing and maintaining the cocaine habit in human addicts.
Keywords: hypocretin, orexin, cocaine, reward, addiction, intracranial self-stimulation, intravenous
self-administration, knockout mice
INTRODUCTION
Cocaine dependence in humans is characterized by persistent
drug use despite negative consequences and high rates of relapse
to drug-taking behavior following intermittent periods of absti-
nence (Dackis and O’Brien, 2001). Hypocretin-1 (Hcrt-1) and
hypocretin-2 (Hcrt-2), also known as orexin-A (OXA) and
orexin-B (OXB), are lateral hypothalamic (LH) neuropeptides
that have garnered much attention since their discovery in the
late 1990s (Gautvik et al., 1996; De Lecea et al., 1998; Sakurai
et al., 1998). While originally considered important regulators
of metabolic, circadian, and stress systems (Lubkin and Stricker-
Krongrad, 1998; VanDen Pol et al., 2001; Szekely, 2006), hypocre-
tin transmission is emerging as a key signaling mechanism in
relapse to drug-seeking during periods of abstinence (Dileone
et al., 2003; Harris et al., 2005; Aston-Jones et al., 2009; Borgland
et al., 2010). Hypocretin fibers innervate, and there are dense con-
centrations of hypocretin receptors, in brain regions implicated
in drug reinforcement processes, such as the nucleus accum-
bens (Acb), ventral tegmental area (VTA), and bed nucleus of
the stria terminalis (BNST) (Peyron et al., 1998; Nambu et al.,
1999; Baldo et al., 2003). Moreover, the hypocretin-1 receptor
(Hcrt-R1) antagonist, SB-334867, has been shown to attenuate
stress- and cue-induced reinstatement of previously extinguished
cocaine-, morphine-, and alcohol-seeking behavior (Boutrel et al.,
2005; Harris et al., 2005; Lawrence et al., 2006; Kenny, 2011).
These findings support the notion that Hcrt-R1 antagonists may
have therapeutic utility for preventing relapse to cocaine use
during periods of abstinence.
While Hcrt-R1 play a role in reinstating drug-seeking behav-
iors, their role in regulating ongoing drug-taking behavior is
much less clear. This is important to understand, as a role for
Hcrt-R1 in the persistence of drug-taking behavior would sug-
gest that Hcrt-R1-based therapeutic agents may have utility not
just in reducing rates of relapse but also in cessation of intake
and achieving abstinence. Aston-Jones and colleagues found that
SB-334867 had no effects on cocaine self-administration when
rats responded for the drug on a fixed-ratio 1 schedule (Smith
et al., 2009). However, SB-334867 significantly decreased cocaine
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self-administration behavior when rats were responding under
more stringent progressive-ratio (PR) schedules of reinforcement
(Borgland et al., 2009; Espana et al., 2010). Similarly, SB-334867
decreased cocaine intake in rats responding vigorously under a
discrete-trial (DT) procedure that limits access to the drug to 10-
min trials interspaced by 20-min intervals when drug access is
withheld during 24-h long access sessions (Espana et al., 2010).
These findings demonstrate that Hcrt-R1 may regulate ongo-
ing cocaine intake, but that this effect occurs most prominently
under reinforcement schedules that require high levels of effort
andmotivation to obtain the drug [for review, see Thompson and
Borgland (2011)].
In addition to the schedule of reinforcement, the effects of
SB-334867 on responding for cocaine in rats also depends upon
a number of other factors, including food deprivation state of the
animal, formulation of the compound (i.e., poor solubility), and
the time of day (i.e., light/dark cycle) of testing. It is a notable
concern that SB-334867 is derived from a chemical scaffold that
generates compounds that can bind to non-Hcrt-R1 receptor tar-
gets including 5-HT2b and 5-HT2c receptors (Porter et al., 2001),
which are relatively unstable in vivo with a short half-life and
could therefore potentially yield bioactive metabolites. Further,
the drug may have poor penetration in the central nervous sys-
tem. Thus, it is possible that in addition to its effects on Hcrt-R1,
SB-334867 could regulate cocaine intake through “off-target”
actions at other classes of receptors in the brain. Considering that
the vast majority of studies implicating Hcrt-R1 in addiction-
related processes have utilized SB-334867, it is important to
verify that the actions of the compound are directly related to
antagonism of Hcrt-R1.
Here, we sought to determine the role for Hcrt-R1 in reg-
ulating ongoing cocaine self-administration behavior by first
assessing the effects of SB-334867 on cocaine self-administration
in rats. Next, we examined whether SB-334867 may modulate
cocaine intake by impacting the reward-enhancing effects of
cocaine, as measured by cocaine-induced lowering of intracra-
nial self-stimulation (ICSS) thresholds in rats. Importantly, the
reward-enhancing effects of cocaine are thought to provide a
major source of motivation that contributes to the establishment
and maintenance of the drug-taking habit (Kenny, 2007). Finally,
to unambiguously test the role for Hcrt-R1 in regulating cocaine-
taking behavior we assessed IV cocaine self-administration in
mice with a null mutation of the Hcrt-1 receptor (Hcrt-R1−/−) in
comparison with their heterozygous (Hcrt-R1+/−) and wildtype
(Hcrt-R1+/+) littermates.
MATERIALS ANDMETHODS
SUBJECTS
For the rat experiments, 24 male Wistar rats in total were
used. Rats weighed 300–320 g upon arrival at the laboratory
(Charles River Laboratories, Raleigh, NC, USA). In the mouse
experiments, we obtained breeding pairs of Hcrt-R1+/− mice
backcrossed > 10 generations on a C57BL/6 mice background
from Jackson Laboratory (Bar Harbor, ME). Mice for testing
were obtained from crosses of heterozygous Hcrt-R1 male and
female mice. For all experiments, rats and mice were housed
in groups of 1–3 per cage, with food and water available ad
libitum, in a temperature-controlled vivarium under a reversed
12-h light/dark cycle (lights off at 8 am). Animals were tested
during the dark portion of the light/dark cycle between the
hours of 11 am and 4 pm. All procedures were conducted in
adherence with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were approved by the
Institutional Animal Care and Use Committee of The Scripps
Research Institute.
DRUGS
SB-334867 [N-(2-Methyl-6-benzoxazolyl)-N′′-1,5-naphthyridin-
4-yl urea hydrochloride] was purchased from Tocris Bioscience
(MO, USA). Cocaine was supplied by the National Institute
on Drug Abuse (NIDA). For IV self-administration, cocaine
was dissolved in 0.9% (w/v) sterile saline, and IV infusions
were earned by rats in a volume of 0.1ml per 4-s infusion
(0.5mg/kg/infusion) or mice in a volume of 35.25μl per 3-s infu-
sion (0.3mg/kg/infusion). For systemically administered cocaine
injections in ICSS experiments, cocaine was dissolved in ster-
ile saline and injected intraperitoneally (IP) in a volume of
1ml/kg body weight. Cocaine was administered 10min before
ICSS experimental sessions. For systemic SB-334867 administra-
tion, SB-334867 was dissolved in 10:10:80, DMSO:tween 80:water
(v:v:v) and delivered in a volume of 10ml/kg body weight by
IP injection 30min before behavioral test sessions. Drugs were
prepared freshly immediately before each administration.
SURGERY
Rats andmice to be prepared with IV catheters were anaesthetized
by inhalation of 1–3% isoflurane in oxygen and silastic catheters
were inserted into the jugular vein as described previously (Fowler
et al., 2011). Briefly, the catheters consisted of a 14 cm (rat) or
6 cm (mouse) length of silastic tubing fitted to a guide cannula
(Plastics one, Wallingford, CT), bent at a curved right angle and
encased in dental acrylic. The catheter tubing was passed sub-
cutaneously from the animals’ back to the right jugular vein,
and 1 inch (rat) or 1 cm length (mouse) of the catheter tip was
inserted into the vein. After surgery, catheters were flushed daily
with 0.1ml of a heparinized (30USP units/ml) sterile saline solu-
tion. Rats to be prepared with ICSS electrodes were anaesthetized
by inhalation of 1–3% isoflurane in oxygen and positioned in
a stereotaxic frame (Kopf Instruments, Tujunga, CA, USA). A
stainless steel bipolar stimulating electrode (11mm in length) was
implanted into the posterior lateral hypothalamus (AP: −0.5mm
from bregma; ML: ±1.7mm; DV: 8.3mm from dura; incisor bar
adjusted to 5mm above the interaural line) (Pellegrino et al.,
1979). Animals were allowed to recover from surgery for at
least 7 days prior to training in the ICSS or self-administration
procedures.
INTRAVENOUS (IV) COCAINE SELF-ADMINISTRATION PROCEDURE
Mice and rats were mildly food restricted to 85–90% of their free-
feeding body weight and trained to press a lever in an operant
chamber (Med Associates, St. Albans, VT) for food pellets (20mg
food pellets, mice; 45mg food pellets, rats; TestDiet, Richmond,
IN) under a fixed-ratio 5, time out 20-s (FR5TO20 s) sched-
ule of reinforcement prior to catheter implantation. Once stable
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responding was achieved (> 25 pellets per session in mice; > 90
pellets per session in rats), subjects were catheterized as described
above. The animals were allowed at least 48 h to recover from
surgery, and then permitted to respond for food reinforcement
again under the FR5TO20 s schedule. Once food-responding cri-
teria were re-established, subjects were permitted to acquire IV
cocaine self-administration by autoshaping during 1-h daily ses-
sions, 7 days per week. Cocaine was delivered through the tubing
into the IV catheter by a Razel syringe pump (Med Associates).
Each cocaine self-administration session was performed using
2 retractable levers (1 active; 1 inactive). Completion of the
response criteria on the active lever resulted in the delivery of
an IV cocaine infusion (0.03ml infusion volume for mice; 0.1ml
for rats). Unit doses of cocaine contingently delivered upon com-
pletion of schedule requirements were 0.5mg/kg/infusion for rat
and 0.3mg/kg/infusion for mouse. Delivery of a cocaine infusion
coincided with the initiation of a 20-s time-out (TO) period, sig-
naled by a light cue located above the lever. During the TO period,
responding on the lever was recorded but without scheduled con-
sequence. Responding on the inactive lever was recorded but also
was without scheduled consequence throughout the session.
INTRACRANIAL SELF-STIMULATION REWARD THRESHOLD
PROCEDURE
Rats (n = 10) were food restricted to maintain body weight
∼85% of free-feeding body weight and trained to respond accord-
ing to a modification of a DT current threshold procedure
(Kornetsky and Esposito, 1979; Markou and Koob, 1992). Briefly,
a trial was initiated by the delivery of a non-contingent electrical
stimulus. This electrical reinforcer had a train duration of 500ms
and consisted of 0.1ms square wave pulses that were delivered at
a frequency of 50–100Hz. The frequency of the stimulation was
selected for individual animals so that current-intensity thresh-
olds (see below) of each subject were within 50–300μA, and thus
allowed both threshold elevation and lowering to be detected.
This frequency for each rat was held constant throughout the
experiment. A one-quarter turn of the wheel manipulandum
within 7.5 s of the delivery of the non-contingent electrical stim-
ulation resulted in the delivery of an electrical stimulus identical
in all parameters to the non-contingent stimulus that initiated
the trial. After a variable inter-trial interval (7.5–12.5 s, aver-
age of 10 s), another trial was initiated with the delivery of a
non-contingent electrical stimulus. Failure to respond to the non-
contingent stimulus within 7.5 s resulted in onset of the inter-trial
interval. Responding during the inter-trial interval reset the inter-
trial interval and thereby delayed the onset of the next trial.
Current levels were varied in alternating descending and ascend-
ing series. A set of five trials was presented for each current
intensity. Current intensities were altered in 5μA steps. In each
testing session, four alternating descending and ascending series
were presented. The threshold for each series was defined as the
midpoint between two consecutive current intensities that yielded
“positive scores” (animals responded for at least three of the five
trials) and two consecutive current intensities that yielded “neg-
ative scores” (animals did not respond for three or more of the
five trials). The overall threshold of the session was defined as the
mean of the thresholds for the four individual series. Each testing
session was approximately 45min in duration. The time between
the onset of the non-contingent stimulus and a positive response
was recorded as the response latency. The response latency for
each test session was defined as the mean response latency of all
trials during which a positive response occurred. After establish-
ment of stable ICSS reward thresholds (defined as≤10%variation
in thresholds over a 3-day period), rats were tested in the ICSS
procedure once daily.
EXPERIMENTAL PROCEDURES
Cocaine self-administration in rats
Rats and mice were prepared with IV catheters and trained to
respond for cocaine infusions as described above. Rats (n = 7)
responding stably for cocaine infusions under a FR5TO20 s
schedule of reinforcement were injected with SB-334867 (0,
1, 2, or 4mg/kg; 30-min pre-treatment) according to a within-
subjects Latin-square design. A minimum of 48 h was allowed
between each SB-334867 injection, during which rats had their
daily cocaine self-administration session, to ensure that rates
of responding for cocaine returned to pre-injection baseline
before the next SB-334867 administration. A second group of
rats (n = 7) responding for food rewards under the same rein-
forcement schedule were injected with SB-334867 (0–4mg/kg;
30-min pre-treatment) according to a within-subjects Latin-
square design, and food intake was assessed.
Intracranial self-stimulation in rats
The dose of cocaine (10mg/kg) used in the present studies was
chosen based on previous observations that this dose induced
maximal threshold lowering without affecting performance in the
ICSS procedure used in the present study (Kenny et al., 2003)
and was equivalent to the amount of cocaine consumed by self-
administering rats during their daily 1-h access to cocaine self-
administration. Rats (n = 10) were prepared with ICSS electrodes
as described above and trained in the ICSS procedure until stable
thresholds were achieved (≤10% variation in thresholds over 5
consecutive days). To determine if SB-334867 attenuated themag-
nitude of cocaine-induced lowering of ICSS thresholds, rats were
injected with SB-334867 (0, 1, 2, 4, mg/kg; 30-min pre-treatment)
according to a within-subjects Latin-square design. All rats then
received a cocaine injection 20min later, 10min prior to initia-
tion of the ICSS session. After this treatment regimen, rats were
once again injected with SB-334867 (0, 1, 2, 4,mg/kg; 30-min pre-
treatment) according to a within-subjects Latin-square design,
but this time the injection given 10min before the ICSS session
was saline instead of cocaine.
Cocaine self-administration in mice
Hcrt-R1 wildtype, heterozygous, and homozygous knockout
mice were trained to respond for food rewards, prepared with
IV catheters, and permitted to respond for cocaine infusions
(0.3mg/kg/infusion; training dose) as described above. After
mice established stable responding for the training dose, the
unit dose available for consumption was varied to generate a
dose-response function. All mice responded for each unit dose
of cocaine in the dose-response curve for at least 5 days and were
returned to the training dose for at least three successive days until
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stable levels of intake at that dose were again established between
the different doses of cocaine tested.
STATISTICAL ANALYSES
The effects of SB-336967 on cocaine intake and responding for
food reinforcers in rats were analyzed by one-factor repeated-
measures analysis of variance (ANOVA) with SB334867 dose
(0–4mg/kg) as the within-subjects repeated-measures factor. For
the ICSS experiment, percentage change from baseline reward
threshold was calculated by expressing the drug-influenced abso-
lute threshold scores as a percentage of the baseline thresh-
olds defined as the mean of the thresholds obtained on the
3 days before the first SB-334867 injection. Next, the percent-
age of baseline scores were subjected to two-factor repeated-
measures ANOVA, with SB-334867 (0–4mg/kg) and cocaine
(0 or 10mg/kg) as the two within-subjects factors. Response
latency data were analyzed in the same manner as the thresh-
old data. For the mouse cocaine self-administration experiment,
data were analyzed by two-factor repeated-measures ANOVA
with cocaine dose as the within-subjects factor and genotype as
the between-subjects factor. Similarly, the food responding data
in mice were analyzed by one-factor repeated-measures ANOVA
with genotype as the between-subjects factor. Significant main
or interaction effects were followed by Bonforroni post-tests or
Newman–Keuls post-hoc tests as appropriate. All statistical analy-
ses were performed using Graphpad Prism software and the level
of significance was set at 0.05.
RESULTS
Hcrt-R1 REGULATES COCAINE SELF-ADMINISTRATION BEHAVIOR
IN RATS
We first investigated the role of hypocretin transmission at
Hcrt-R1 in regulating cocaine self-administration behav-
ior in rats. Rats responding for IV cocaine infusions
(0.5mg/kg/infusion) under a FR5TO20 s schedule of rein-
forcement were treated with the selective Hcrt-R1 antagonist
SB-334867 (0, 1, 2, and 4mg/kg IP) and cocaine intake mea-
sured. To identify possible non-specific actions of SB-334867 on
operant performance, we also assessed the effects of the drug
on responding for food pellets in food restricted rats tested
under the same reinforcement schedule. The mean number
of food or cocaine rewards earned prior to treatment with
SB-334867 was 94.3 ± 4.6 and 22.1 ± 1.9, respectively. One-Way
repeated-measures ANOVA on the cocaine intake data following
SB-334867 treatment revealed that SB-334867 significantly
altered cocaine self-administration [F(3, 27) = 14.5, P < 0.0001].
Bonferroni post-tests among means revealed that cocaine intake
was significantly reduced at the 2mg/kg (P < 0.05) and 4mg/kg
(P < 0.001) compared with vehicle treatment (Figure 1A). In
contrast, One-Way repeated-measures ANOVA on the food
intake data demonstrated no statistically significant effects
of SB-334867 at any dose tested [F(3, 27) = 0.6, P > 0.05;
Figure 1B].
Hcrt-R1 REGULATE THE REWARD-ENHANCING EFFECTS OF COCAINE
Similar to other drugs of abuse, cocaine enhances the activity
of the brain reward systems, as measured by lowering of ICSS
FIGURE 1 | Hypocretin transmission at Hcrt-1 receptors regulates
cocaine intake. The effects of systemically administered SB-334867 on
responding for cocaine or food rewards were tested under a FR5TO20 s
reinforcement schedule (see Materials and Methods). (A) Mean (± S.E.M.)
number of cocaine reinforcers earned after treatment with the selective
Hcrt-R1 antagonist SB-334867. ∗P < 0.05 and ∗∗∗P < 0.001 compared with
vehicle treatment; post-hoc test after a significant main effect in One-Way
repeated-measures ANOVA. (B) Mean (± S.E.M.) number of food
reinforcers earned after treatment with SB-334867.
thresholds (Esposito et al., 1978; Maldonado-Irizarry et al., 1994).
One mechanism by which SB-334867 could decrease cocaine
intake in rats is by attenuating the stimulatory effects of cocaine
on brain reward systems. To test this hypothesis, we assessed the
effects of SB-334867 (0, 1, 2, and 4mg/kg IP) on cocaine-induced
lowering of ICSS thresholds in rats. Mean absolute ICSS thresh-
olds prior to SB-334867 treatment was 115.5 ± 10.5μA. Two-
Way repeated-measures ANOVA demonstrated a significant main
effect of cocaine [F(1, 16) = 83.09, P < 0.0001] and significant
SB-334867 X cocaine interaction [F(3, 16) = 8.61, P < 0.01], but
no effect of SB-334867 [F(3, 16) = 2.62, P > 0.05]. Pre-planned
comparisons among means demonstrated that reward thresh-
olds were significantly lowered by vehicle-cocaine (P < 0.0001)
treatment compared with vehicle-saline treatment. Pre-treatment
with the lowest doses of SB-334867 (0–2mg/kg) did not alter the
threshold-lowering effects of cocaine compared with saline treat-
ment (Figure 2). However, pre-treatment with the highest dose
of SB-334867 (4mg/kg) completely blocked this effect of cocaine.
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FIGURE 2 | Hypocretin transmission at Hcrt-1 receptors regulates the
reward-enhancing effects of cocaine. The effects of SB-334867 on
cocaine-induced lowering of ICSS thresholds were tested. Rats were
pre-treated with SB-334867 (0, 1, 2, or 4mg/kg), and subsequently received
saline or cocaine (10mg/kg) injections. Data are expressed as mean
(± S.E.M.) percentage change from baseline thresholds. ∗∗P < 0.01 and
∗∗∗P < 0.001 compared with the saline pre-treatment at the same dose of
SB-334867; post-hoc comparisons after significant main effect of Cocaine
and interaction effect with SB-334867 in Two-Way repeated-measures
ANOVA.
Response latencies were unaltered by any treatment condition
(data not shown).
Hcrt-1 KNOCKOUT MICE ARE LESS SENSITIVE TO COCAINE
REINFORCEMENT
Although the Hcrt-R1 antagonist SB-334867 is 50-fold more
selective for Hcrt-R1 over the Hcrt-R2 receptor (Smart et al.,
2001), as with all other pharmacological probes there is the
possibility that it may act at other receptor targets (Porter
et al., 2001). Thus, to verify that the Hcrt-R1 indeed regu-
lates ongoing cocaine-taking behavior, we assessed cocaine self-
administration in Hcrt-R1−/−, Hcrt-R1+/−, and Hcrt-R1+/+
mice. A Two-Way repeated-measures ANOVA revealed significant
main effects for genotype [F(2, 36) = 4.2, P < 0.05] and cocaine
dose [F(3, 36) = 12.9, P < 0.0001], with a significant genotype X
cocaine dose interaction [F(6, 36) = 4.3, P < 0.01]. Bonferroni
post-tests among means revealed that cocaine intake was sig-
nificantly reduced in the Hcrt-1−/− compared to the Hcrt-
1+/+ mice at the 0.3mg/kg (P < 0.001) and 1mg/kg (P < 0.05)
cocaine doses (Figure 3A). One-Way repeated-measures ANOVA
on the food intake data demonstrated no statistically significant
effects of genotype across the 14 days of food self-administration
[F(2, 152) = 2.79, P > 0.05; Figure 3B].
DISCUSSION
Our findings support the growing literature showing that
hypocretin is a critical signaling neuropeptide that regulates the
motivational and psychomotor stimulant properties of cocaine
and other drugs of abuse. Previous work has shown that blockade
FIGURE 3 | Genetic deletion of Hcrt-1 receptors greatly diminishes the
reinforcing properties of cocaine. Responding for cocaine and food
reward was tested in Hcrt-R1−/− , Hcrt-R1+/− , and Hcrt-R1+/+ mice. Data
is expressed as mean (± S.E.M.) number of cocaine (A) or food (B)
reinforcers earned on a FR5TO20 schedule of reinforcement. ∗P < 0.05 and
∗∗∗P < 0.001 compared Hcrt-R1+/+ to Hcrt-R1−/− mice; post-hoc
comparisons made after Two-Way repeated-measures ANOVA calculated.
of Hcrt-R1 transmission decreases locomotor sensitization to
cocaine (Borgland et al., 2006) and attenuates the reinstate-
ment of previously extinguished responding for the drug (Boutrel
et al., 2005; Smith et al., 2009; James et al., 2011). Here, we
show that the selective Hcrt-R1 antagonist SB-334867 decreases
cocaine (but not food) self-administration in rats. Further, we
found that SB-334867 dose-dependently blocked the stimulatory
effects of cocaine on brain-reward circuitry, as measured by ICSS
thresholds. Finally, we show for the first time that mice lack-
ing functional Hcrt-R1 (Hcrt-R1−/−) exhibit greatly diminished
responsiveness to the self-administration of cocaine. Collectively,
these findings suggest that Hcrt-1 signaling is essential for main-
taining ongoing cocaine-taking behavior and may be a promising
target in the development of pharmacotherapies to treat cocaine
dependence.
Our findings further show that blockade of Hcrt-R1 transmis-
sion using the selective antagonist SB-334867 dose-dependently
decreased cocaine intake in rats at doses that did not alter
responding for food reinforcers. Importantly, previous work from
Frontiers in Behavioral Neuroscience www.frontiersin.org July 2012 | Volume 6 | Article 47 | 5
Hollander et al. Hypocretin (orexin) and cocaine reward
our laboratory has shown that the low dose of SB-334867 used in
this study (4mg/kg; IP) was still detectable in brain tissues and
blood 2 h following administration (Hollander et al., 2008). Our
rationale for selecting low doses of SB-334867 in our studies is
based on evidence that doses greater than 10mg/kg can produce
disturbances in sleep/awake cycles (Smith et al., 2003) as well as
a number of active behaviors (feeding, grooming, sniffing, loco-
motion, and rearing) (Rodgers et al., 2001). Nevertheless, our
findings suggest that Hcrt-R1 play an essential role in maintain-
ing ongoing cocaine intake and highlight the possibility that novel
Hcrt-R1 antagonists suitable for use in humans may have thera-
peutic utility for the treatment of cocaine dependence. It is impor-
tant to note that previous studies have provided mixed results
with regard to the role for Hcrt-R1 in cocaine reinforcement.
Aston-Jones and colleagues have shown that SB-334867 does not
decrease cocaine intake in rats responding under a FR1 sched-
ule of reinforcement (Smith et al., 2009). In contrast, SB-334867
decreased cocaine intake in rats responding under schedules
requiring greater degrees of effort and motivation to obtain the
drug (PR and DT reinforcement schedules; see Introduction)
(Borgland et al., 2009; Espana et al., 2010). In our study, rats
responded under a FR5 schedule, which requires greater levels of
effort to obtain the drug than FR1 schedules. While we did not
manipulate the reinforcement schedule in our experiments, we
speculate that SB-334867 and genetic knockout of the Hcrt-R1 are
most effective in reducing cocaine self-administration when effort
requirements are high. For example, we plan to test in future stud-
ies the hypothesis that Hcrt-R1−/− may show more similar levels
of cocaine intake to Hcrt-R1+/+ under an FR1 schedule, but
would exhibit decreased responding as the effort to obtain cocaine
is increased (e.g., FR-5, PR). Nevertheless, our findings support a
key role for Hcrt-R1 in cocaine reinforcement, and further sup-
port the notion that the effects of Hcrt-R1 transmission in this
process are dependent on the degree of motivation required to
seek and obtain the drug.
With extensive evidence demonstrating the importance of
hypocretin in arousal state (Moore et al., 2001; Yoshimichi
et al., 2001; Sasaki et al., 2011; Tsunematsu et al., 2011), it
is possible that the decreased effects of cocaine we observed
following the blockade of Hcrt-R1 signaling is due to a gener-
alized disruption of stress systems. Certainly, there is a strong
link between hypocretin functioning and biochemical modula-
tion of stress pathways in the CNS. For example, it has been
shown that the non-selective corticotropin-releasing factor (CRF)
receptor antagonist α-helical CRF blocked hypocretin-induced
grooming and face-washing behaviors in rats (Ida et al., 2000).
Further, administration of the Hcrt-1 peptide dose-dependently
increased circulating corticosterone levels and central expression
of CRF mRNA (Ida et al., 2000; Al-Barazanji et al., 2001; Russell
et al., 2001). Additionally, Boutrel and colleagues found that ICV
administration of the Hcrt-1 peptide elevated ICSS thresholds,
which indicates a decrease in the activity of brain reward systems
(Boutrel et al., 2005). Based on these observations, it is plausible
that hypocretins regulate the reinforcing effects of cocaine by neu-
ral circuitry associated with stress and arousal-related processes.
However, as shown here and in a prior report from our labora-
tory (Hollander et al., 2008), SB-334867 administration alone did
not elevate ICSS thresholds in rats, an increase that is indicative
of dysphoria or an aversive state (Carlezon and Chartoff, 2007),
and which may be expected in the case of increased CRF signal-
ing (Macey et al., 2000; Bruijnzeel et al., 2009). While there are
reports that show Hcrt-R1−/− mice have fragmented sleep/wake
cycles (Willie et al., 2003; Mieda et al., 2011), many groups
have found that these animals do not appear to have an overt
arousal/stress phenotype or behavioral abnormalities (Hungs and
Mignot, 2001; Willie et al., 2001; Sakurai, 2007; Hondo et al.,
2010). Therefore, our data support the notion that Hcrt-R1 have
a critical role in cocaine reinforcement that, at least in part, can
act independent of endogenous stress systems.
The ICSS procedure used here is based on the premise that
electrical self-stimulation of certain brain areas (e.g., lateral
hypothalamus, VTA) is highly rewarding and may be a useful
strategy when assessing changes in the motivational influences
of cocaine (Kornetsky and Esposito, 1979; Fish et al., 2010). In
our studies, the ICSS procedure gives a significant advantage over
the self-administration experiments in that it is possible to obtain
a physiological measure of the stimulatory effects of cocaine
on brain reward systems. The ICSS reward threshold is defined
as the minimum electrical current necessary to support self-
stimulation behavior by the animal and is remarkably consistent
across test sessions. Thus, the ICSS procedure is considered an
accurate measure of how well brain reward systems are function-
ing. Importantly, acute administration of cocaine and all other
major drugs of abuse have been shown to lower the ICSS thresh-
old (Markou and Koob, 1992; Bespalov et al., 1994; Harrison
et al., 2002), while drug withdrawal diminishes brain reward
function and elevates ICSS thresholds (Ahmed et al., 2002; Kenny
andMarkou, 2005; Bruijnzeel et al., 2007). Obtaining the reward-
enhancing properties of cocaine, reflected in its lowering effects
on ICSS thresholds (Esposito et al., 1978; Maldonado-Irizarry
et al., 1994), is thought to provide an important source of motiva-
tion that contributes to the establishment and maintenance of the
cocaine-taking habit (Kenny, 2007). The cocaine-induced lower-
ing of the ICSS threshold was dose-dependently blocked with the
Hcrt-1 antagonist, suggesting that SB-334867 reduces the reward-
enhancing effects of cocaine. These results are reminiscent of
recent findings from our laboratory showing that similar doses of
SB-334867 abolished nicotine-induced lowering of ICSS thresh-
olds in rats (Hollander et al., 2008). However, this result appears
to conflict with a recent report by Riday and colleagues who
found that SB-334867 had no effects on the cocaine-enhanced
responding for ICSS in Swiss-Webster mice (Riday et al., 2012).
Importantly, mice responded for ICSS in this prior study under
a continuous reinforcement schedule (FR1), which requires low
levels of effort to obtain rewarding ICSS (Riday et al., 2012).
In contrast, responding for ICSS in our study occurred under
a DT current-threshold procedure that requires greater degrees
of effort and motivation to obtain stimulation compared with
FR1 schedules. As noted above, SB-334867 does not appear to
decrease cocaine intake in rats responding under a FR1 reinforce-
ment schedule (Smith et al., 2009), but decreases intake in rats
responding under schedules requiring higher levels of motivation
(Borgland et al., 2009; Espana et al., 2010). Hence, the apparent
discrepancy between our current study and that of Riday and
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colleagues likely reflects the levels of effort required to obtain ICSS
in both studies.
We found that heterozygous or homozygous for null muta-
tion in Hcrt-R1 demonstrated a gene-dosage-type decrease in
responding for cocaine across the entire dose-response function,
typically interpreted as a decrease in motivation to consume
cocaine. Importantly, these mice did not show any deficit in
responding for food reinforcers under the same reinforcement
schedule. In fact, there was a trend for the Hcrt-R1+/− and Hcrt-
R1−/− to responding at higher rates for food reinforcers. This ver-
ifies that the decreased responding for cocaine seen in these mice
was not secondary to disruption in learning- or performance-
related processes that could indirectly have resulted in lower levels
of lever-pressing for cocaine. These findings provide definitive
evidence that Hcrt-R1 is essential for the reinforcing properties
of cocaine. A distinct disadvantage of using Hcrt-1 knockout
mice in our study is the possibility that the behavioral effects
observed are due to genetic compensation mechanisms, such as
altered expression of Hcrt-2 receptor signaling in these animals.
Intriguingly, both hypocretin receptor subtypes are concentrated
in a number of brain areas important for reward-related pro-
cessing, including the VTA, accumbens, BNST, and CeA (Peyron
et al., 1998; Nambu et al., 1999; Narita et al., 2006). However,
to date, there has been very little evidence suggesting a promi-
nent role for Hcrt-2 transmission in mediating the rewarding
properties of drugs of abuse such as cocaine. For example, VTA
perfusion of Hcrt-1 (but not Hcrt-2) was found to increase
VTA release of glutamate and dopamine, as well as success-
fully reinstate extinguished cocaine seeking (Wang et al., 2009).
While transgenic mice with both receptors knocked out showed
reduced dopaminergic responses to cocaine (Espana et al.,
2010), the Hcrt-R1 antagonist SB334867 was found to block the
effects of cocaine on glutamatergic plasticity of VTA dopamine
neurons (Borgland et al., 2006). In addition, administration
of the Hcrt-2 receptor antagonist 4-pyridylmethyl (S)-tert-
leucyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (4PT) had
no effect on cocaine intake and cue-induced reinstatement in
rats (Smith et al., 2009). Furthermore, while repeated cocaine
injections in rats showed upregulated Hcrt-2 protein levels in
the accumbens, this effect was not found in several other impor-
tant reward-related limbic structures including the frontal cor-
tex, hippocampus, VTA, and caudate putamen (Zhang et al.,
2007). Although these observations suggest that alterations in
Hcrt-2 receptors are unlikely to account for our findings, other
compensatory mechanisms independent of Hcrt-1 signaling
could potentially contribute to the deficits in drug intake in
the heterozygous and knockout mice. To account for this pos-
sibility, future investigations will need to evaluate cocaine self-
administration in mice with conditional deletion of Hcrt-R1 in
a spatially and temporally controlled fashion, or animals where
virus is used to re-express the missing Hcrt-1 gene in targeted
brain sites.
In sum, our findings suggest that hypocretin transmission at
Hcrt-R1 may be a critical signaling cascade in the rewarding
and motivational properties of cocaine. As such, there may be a
tremendous potential therapeutic utility of Hcrt-R1 antagonists
in the treatment of cocaine dependency in addicts who wish to
remain drug-free.
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